Barclays
EWTX icon

Barclays’s Edgewise Therapeutics EWTX Stock Holding History

Barclays’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.47M Sell
60,887
-129,318
-68% -$5.5M ﹤0.01% 2454
2026
Q2 		$7.73M Buy
190,205
+12,961
+7% +$447K ﹤0.01% 1615
2026
Q1 		$5.58M Sell
177,244
-195,494
-52% -$5.64M ﹤0.01% 1753
2025
Q4 		$9.25M Buy
372,738
+138,088
+59% +$2.77M ﹤0.01% 1734
2025
Q3 		$3.81M Sell
234,650
-46,600
-17% -$661K ﹤0.01% 2403
2025
Q2 		$3.69M Buy
281,250
+172,688
+159% +$2.49M ﹤0.01% 2361
2025
Q1 		$2.39M Sell
108,562
-25,095
-19% -$658K ﹤0.01% 2496
2024
Q4 		$3.57M Buy
133,657
+14,307
+12% +$456K ﹤0.01% 2448
2024
Q3 		$3.19M Buy
119,350
+88,826
+291% +$1.77M ﹤0.01% 2466
2024
Q2 		$550K Sell
30,524
-56,720
-65% -$989K ﹤0.01% 2984
2024
Q1 		$1.59M Sell
87,244
-691,672
-89% -$11M ﹤0.01% 2763
2023
Q4 		$8.52M Buy
778,916
+760,637
+4,161% +$5.34M ﹤0.01% 1634
2023
Q3 		$105K Buy
18,279
+1,003
+6% +$6.82K ﹤0.01% 3586
2023
Q2 		$134K Sell
17,276
-10,740
-38% -$90.6K ﹤0.01% 3436
2023
Q1 		$187K Buy
28,016
+9,783
+54% +$90.7K ﹤0.01% 3828
2022
Q4 		$163K Buy
18,233
+8,918
+96% +$83.6K ﹤0.01% 3961
2022
Q3 		$91K Sell
9,315
-209,993
-96% -$2.12M ﹤0.01% 3570
2022
Q2 		$1.75M Sell
219,308
-652
-0.3% -$4.93K ﹤0.01% 1952
2022
Q1 		$2.13M Buy
+219,960
New +$2.83M ﹤0.01% 1808

Other funds holding EWTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Tyro Capital Management
Tyro Capital Management Miami, Florida $564M AUM 72.37% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Barclays's EWTX Position: Q3 2026 in Review

Barclays reduced its Edgewise Therapeutics (EWTX) stake by 68% in Q3 2026, selling an estimated $5.5M and leaving 60,887 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

Barclays first reported a position in EWTX in Q1 2022 and has held it in 19 quarters since. The position peaked at $9.25M in Q4 2025. 105 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

  • Barclays held 60,887 shares of Edgewise Therapeutics worth $2.47M as of Q3 2026.
  • Barclays sold 129,318 Edgewise Therapeutics shares in Q3 2026, an estimated $5.5M.
  • Edgewise Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2454 holding.
  • Barclays first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Edgewise Therapeutics position peaked at $9.25M in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.